Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru. Issue 26 (9th June 2022)

• Record Type: Journal Article
• Authors: De-Los-Rios-Pinto, Abraham; Fernandez-Guzman, Daniel; Soriano-Moreno, David R.; Sangster-Carrasco, Lucero; Morocho-Alburqueque, Noelia; Pinedo-Soria, Antony; Murrieta-Ruiz, Valentina; Diaz-Corrales, Angelica; Alave, Jorge; Nieto-Gutierrez, Wendy; Gonzales-Zamora, Jose
• Is Part Of: Vaccine. Volume 40:Issue 26(2022)
• Page Start: 3566
• Page End: 3572
• Publication Date: 2022-06-09
• Subjects: COVID-19 -- Coronavirus -- Intention to participate -- Vaccine -- Clinical Trial -- Associated factors; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2022.04.003
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: Most of the Peruvian population did not intend to participate in COVID-19 clinical trials. The main reasons for not participating were the possible side effects, distrust on the efficacy of the vaccine, and believing the vaccine has microchips. To have a medical source of information for COVID-19 increased the intention to participate. Abstract: Objective: To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. Methods: Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. Results: Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15–1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09–1.28) or jungle (RPa: 1.30; 95% CI: 1.15–1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06–1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17–1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29–1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). Conclusion: There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine.